Amgen Inc. (AMGN)
| Market Cap | 248.97B +56.1% |
| Revenue (ttm) | 38.90B +8.2% |
| Net Income | 9.39B +34.1% |
| EPS | 17.26 +33.5% |
| Shares Out | 540.91M |
| PE Ratio | 26.67 |
| Forward PE | 18.88 |
| Dividend | $10.08 (2.19%) |
| Ex-Dividend Date | Nov 20, 2026 |
| Volume | 4,106,795 |
| Open | 483.99 |
| Previous Close | 478.48 |
| Day's Range | 459.65 - 483.99 |
| 52-Week Range | 302.13 - 483.99 |
| Beta | 0.42 |
| Analysts | Hold |
| Price Target | 409.63 (-11.0%) |
| Earnings Date | Nov 3, 2026 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial StatementsAnalyst Summary
According to 34 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $409.63, which is a decrease of -11.00% from the latest price.
News
Amgen’s Repatha lowers heart attack risk 20% vs. ezetimibe in real-world study
Amgen (AMGN) announced results from a large real-world study showing that treatment with Repatha – evolocumab – reduced the risk of fatal or nonfatal heart attacks by 20% compared with…
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY
Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results Provid...
Amgen price target raised to $435 from $378 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Amgen (AMGN) to $435 from $378 and keeps a Neutral rating on the shares.
Amgen price target raised to $530 from $500 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $530 from $500 and keeps an Outperform rating on the shares. The firm believes the company’s commercial…
Amgen price target raised to $398 from $380 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Amgen (AMGN) to $398 from $380 and keeps a Hold rating on the shares. The firm is positive on the…
Amgen price target raised to $470 from $430 at RBC Capital
RBC Capital analyst Luca Issi raised the firm’s price target on Amgen (AMGN) to $470 from $430 and keeps an Outperform rating on the shares. The company delivered a meaningful…
Amgen price target raised to $520 from $480 at Oppenheimer
Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $520 from $480 and keeps an Outperform rating on the shares following quarterly results. The firm notes…
Amgen price target raised to $531 from $452 at TD Cowen
TD Cowen raised the firm’s price target on Amgen (AMGN) to $531 from $452 and keeps a Buy rating on the shares. The firm updated its model following its 3rd…
Amgen price target raised to $410 from $359 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Amgen (AMGN) to $410 from $359 and keeps an Equal Weight rating on the shares.
Amgen price target raised to $347 from $328 at BofA
BofA raised the firm’s price target on Amgen (AMGN) to $347 from $328 and keeps an Underperform rating on the shares after the firm adjusted estimates for Q3 results, product…
Amgen price target raised to $530 from $470 at UBS
UBS raised the firm’s price target on Amgen (AMGN) to $530 from $470 and keeps a Buy rating on the shares. Amgen beat Q3 revenue and EPS estimates and raised…
Amgen price target raised to $465 from $440 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Amgen (AMGN) to $465 from $440 and keeps a Neutral rating on the shares. Amgen delivered broad product-level beats,…
Amgen price target raised to $400 from $345 at Bernstein
Bernstein raised the firm’s price target on Amgen (AMGN) to $400 from $345 and keeps a Market Perform rating on the shares. The firm notes Amgen delivered a 3.4% revenue…
Amgen price target raised to $425 from $350 at JPMorgan
JPMorgan raised the firm’s price target on Amgen (AMGN) to $425 from $350 and keeps a Neutral rating on the shares.
Amgen price target raised to $440 from $384 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on Amgen (AMGN) to $440 from $384 and keeps a Hold rating on the shares. The firm said Q3 had solid…
Amgen price target raised to $465 from $405 at Citi
Citi raised the firm’s price target on Amgen (AMGN) to $465 from $405 and keeps a Buy rating on the shares. The firm says the company’s Q3 report shows its…
Amgen price target raised to $460 from $430 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Amgen (AMGN) to $460 from $430 and keeps an Equal Weight rating on the shares. The firm says strong…
Amgen price target raised to $536 from $481 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Amgen (AMGN) to $536 from $481 and keeps a Buy rating on the shares following the “strong” Q3. The strong commercial momentum…
Amgen Earnings Call Transcript: Q3 2026
Q3 revenue rose 8% to $10.4B as six growth drivers grew 27%. 2026 revenue and non-GAAP EPS guidance rose, backed by late-stage pipeline progress.
Amgen Earnings release: Q3 2026
Amgen released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Amgen Slides: Q3 2026
Amgen has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Amgen Quarterly report: Q3 2026
Amgen has published its Q3 2026 quarterly earnings report on November 3, 2026.
Amgen reports Q3 adjusted EPS $6.45, consensus $5.78
Reports Q3 revenue $10.4B, consensus $10.06B. “Amgen (AMGN) delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise,” said Robert Bradw...
Amgen raises FY26 adjusted EPS view to $22.90-$23.70 from $22.30-$23.50
FY26 consensus $23.02. Raises FY26 revenue view to $38.9B-$39.7B from $38.2B-$39.4B, consensus $38.97B.
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.